CHRS · Coherus Oncology, Inc.

Coherus Oncology reported first quarter 2026 financial results, highlighting a 61% year-over-year increase in LOQTORZI net revenue to $11.8 million, driven by volume growth and new patient starts. Net loss from continuing operations improved to $36.9 million from $47.4 million in the prior year, reflecting lower R&D and SG&A expenses due to headcount reductions and exit from the biosimilar business. The company ended the quarter with $167.0 million in cash, cash equivalents and marketable securities, including TSA-related collections. Management emphasized pipeline progress: the Phase 2 trial for casdozokitug in first-line hepatocellular carcinoma is fully enrolled with initial data expected mid-2026, and the tagmokitug program is on track for multiple data readouts. The company also completed a public equity offering in Q1, raising $53.6 million net proceeds. The results demonstrate continued commercial execution for LOQTORZI and disciplined cost management, while the pipeline milestones represent potential catalysts for the remainder of 2026.